Gaming and Leisure Properties Announces the Acquisition of Three Casino Resorts in South Dakota and Nevada for $105 Million and Establishes New Tenant Relationship With Strategic Gaming Management Transaction is Expected to be Immediately Accretive WYOMISSING, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (“GLPI”) today acquired the real estate assets of the Silverado Franklin Hotel & Gaming Complex (“Silverado”), the Deadwood Mountain Grand (“DMG”) casino, and Baldini’s Casino (“Baldini’s”), for $105.0 million in aggregate. Simultaneous with t...
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the , to take place on Monday, May 20, 2024, at the NAS...
Two Directors at Floor & Decor Holdings Inc sold/sold after exercising options 5,965 shares at between 123.110USD and 124.696USD. The significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWI...
Eos Energy Enterprises Reports First Quarter 2024 Financial Results and Announces Successful Completion of Factory Acceptance Testing Company successfully completes Factory Acceptance Testing on state-of-the-art manufacturing line 1; remains on schedule for Q2 commissioning EDISON, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced financial results for the first quarter ended March 31, 2024. First ...
Two Directors at McDonald's Corp bought/sold 830 shares at between 0.000USD and 275.020USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Eos Energy Enterprises Announces Participation in Upcoming Investor Conferences EDISON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced its participation at two upcoming investor conferences in June. Chief Executive Officer Joe Mastrangelo and Chief Financial Officer Nathan Kroeker will be attending and presenting at the Stifel Cross Sector Insight Conference in Boston on Wednesday, June 5, 2024. Mr...
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not inten...
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress ~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 2...
Eos Energy Announces Approval of All Proposals at 2024 Annual Stockholder Meeting EDISON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced the results of its Annual Stockholders’ Meeting, which was conducted virtually. “We are deeply grateful for the continued support of our stockholders,” said Joe Mastrangelo, CEO of Eos. “We are currently working to bring our first state-of-the-art manufacturi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.